RESUMO
Recent genetic, molecular and post-mortem studies suggest impaired dopamine (DA)-D2 receptor (D2R) trafficking in patients with schizophrenia (SZ). Imaging and preclinical studies have shown agonist-induced D2R internalization can be imaged with positron emission tomography (PET) using D2R radiotracers combined with psychostimulant challenge. This is feasible if radiotracer binding is measured when postchallenge DA levels have returned to baseline, following the initial competition phase between DA and radiotracer for binding to D2R. Here we used 'late-phase' imaging after challenge to test the hypothesis that impaired D2R internalization in SZ leads to blunted late-phase displacement, or a faster return to baseline, in patients compared with healthy controls (HCs). We imaged 10 patients with SZ and 9 HCs with PET and [11C]raclopride at baseline and two times (3-5 and 6-10 h) following 0.5 mg kg-1 dextroamphetamine. We measured binding potential relative to non-displaceable compartment (BPND) and derived percent reduction from baseline (ΔBPND) for each postamphetamine scan. To test the hypothesis that time course of return of striatal BPND to baseline differed between SZ and HCs, we implemented a linear model with ΔBPND as dependent variable, time after amphetamine as repeated measure and time after amphetamine and diagnostic group as fixed effects. Neither diagnostic group nor interaction of diagnostic group-by-time after amphetamine significantly affected striatal ΔBPND (F=1.38, P=0.26; F=0.51, P=0.61). These results show similar pattern of return of BPND to baseline as a function of time in patients with SZ and HC, suggesting that striatal D2R internalization as measured by our imaging paradigm is normal in patients with SZ.
Assuntos
Receptores de Dopamina D2/metabolismo , Esquizofrenia/diagnóstico por imagem , Esquizofrenia/metabolismo , Adulto , Anfetamina/farmacologia , Radioisótopos de Carbono , Estudos de Casos e Controles , Estimulantes do Sistema Nervoso Central/farmacologia , Dextroanfetamina/farmacologia , Dopamina/metabolismo , Agonistas de Dopamina/farmacologia , Feminino , Humanos , Masculino , Tomografia por Emissão de Pósitrons/métodos , Racloprida/metabolismo , Cintilografia/métodosRESUMO
This corrects the article DOI: 10.1038/mp.2017.107.
RESUMO
Most drugs of abuse lead to a general blunting of dopamine release in the chronic phase of dependence, which contributes to poor outcome. To test whether cannabis dependence is associated with a similar dopaminergic deficit, we examined striatal and extrastriatal dopamine release in severely cannabis-dependent participants (CD), free of any comorbid conditions, including nicotine use. Eleven CD and 12 healthy controls (HC) completed two positron emission tomography scans with [11C]-(+)-PHNO, before and after oral administration of d-amphetamine. CD stayed inpatient for 5-7 days prior to the scans to standardize abstinence. Magnetic resonance spectroscopy (MRS) measures of glutamate in the striatum and hippocampus were obtained in the same subjects. Percent change in [11C]-(+)-PHNO-binding potential (ΔBPND) was compared between groups and correlations with MRS glutamate, subclinical psychopathological and neurocognitive parameters were examined. CD had significantly lower ΔBPND in the striatum (P=0.002, effect size (ES)=1.48), including the associative striatum (P=0.003, ES=1.39), sensorimotor striatum (P=0.003, ES=1.41) and the pallidus (P=0.012, ES=1.16). Lower dopamine release in the associative striatum correlated with inattention and negative symptoms in CD, and with poorer working memory and probabilistic category learning performance in both CD and HC. No relationships to MRS glutamate and amphetamine-induced subclinical positive symptoms were detected. In conclusion, this study provides evidence that severe cannabis dependence-without the confounds of any comorbidity-is associated with a deficit in striatal dopamine release. This deficit extends to other extrastriatal areas and predicts subclinical psychopathology.
Assuntos
Cannabis/efeitos adversos , Corpo Estriado/efeitos dos fármacos , Abuso de Maconha/fisiopatologia , Adulto , Anfetamina/farmacologia , Encéfalo/efeitos dos fármacos , Cannabis/metabolismo , Dextroanfetamina/farmacologia , Dopamina , Endocanabinoides/metabolismo , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Abuso de Maconha/metabolismo , Tomografia por Emissão de Pósitrons/métodosRESUMO
Currently, all treatments for schizophrenia (SCZ) function primarily by blocking D(2)-type dopamine receptors. Given the limitations of these medications, substantial efforts have been made to identify alternative neurochemical targets for treatment development in SCZ. One such target is brain glutamate. The objective of this article is to review and synthesize the proton magnetic resonance spectroscopy ((1)H MRS) and positron emission tomography (PET)/single-photon emission computed tomography (SPECT) investigations that have examined glutamatergic indices in SCZ, including those of modulatory compounds such as glutathione (GSH) and glycine, as well as data from ketamine challenge studies. The reviewed (1)H MRS and PET/SPECT studies support the theory of hypofunction of the N-methyl-D-aspartate receptor (NMDAR) in SCZ, as well as the convergence between the dopamine and glutamate models of SCZ. We also review several advances in MRS and PET technologies that have opened the door for new opportunities to investigate the glutamate system in SCZ and discuss some ways in which these imaging tools can be used to facilitate a greater understanding of the glutamate system in SCZ and the successful and efficient development of new glutamate-based treatments for SCZ.
Assuntos
Descoberta de Drogas , Ácido Glutâmico/metabolismo , Esquizofrenia/metabolismo , Esquizofrenia/patologia , Animais , Humanos , NeuroimagemRESUMO
Dopamine (DA) has a role in the pathophysiology of schizophrenia and addiction. Imaging studies have indicated that striatal DA release is increased in schizophrenia, predominantly in the precommissural caudate (preDCA), and blunted in addiction, mostly in the ventral striatum (VST). Therefore, we aimed to measure striatal DA release in patients with comorbid schizophrenia and substance dependence. We used [(11)C]raclopride positron emission tomography and an amphetamine challenge to measure baseline DA D2-receptor availability (BPND) and its percent change post-amphetamine (ΔBPND, to index amphetamine-induced DA release) in striatal subregions in 11 unmedicated, drug-free patients with both schizophrenia and substance dependence, and 15 healthy controls. There were no significant group differences in baseline BPND. Linear mixed modeling using ΔBPND as the dependent variable and striatal region of interest as a repeated measure indicated a significant main effect of diagnosis, F(1,24)=8.38, P=0.008, with significantly smaller ΔBPND in patients in all striatal subregions (all P ≤ 0.04) except VST. Among patients, change in positive symptoms after amphetamine was significantly associated with ΔBPND in the preDCA (rs=0.69, P=0.03) and VST (rs=0.64, P=0.05). In conclusion, patients with comorbid schizophrenia and substance dependence showed significant blunting of striatal DA release, in contrast to what has been found in schizophrenia without substance dependence. Despite this blunting, DA release was associated with the transient amphetamine-induced positive-symptom change, as observed in schizophrenia. This is the first description of a group of patients with schizophrenia who display low presynaptic DA release, yet show a psychotic reaction to increases in D2 stimulation, suggesting abnormal postsynaptic D2 function.
Assuntos
Corpo Estriado/metabolismo , Dopamina/metabolismo , Esquizofrenia/metabolismo , Transtornos Relacionados ao Uso de Substâncias/metabolismo , Adulto , Anfetamina/farmacologia , Estudos de Casos e Controles , Corpo Estriado/diagnóstico por imagem , Corpo Estriado/efeitos dos fármacos , Diagnóstico Duplo (Psiquiatria) , Feminino , Neuroimagem Funcional , Humanos , Masculino , Cintilografia , Esquizofrenia/complicações , Esquizofrenia/diagnóstico por imagem , Transtornos Relacionados ao Uso de Substâncias/complicações , Transtornos Relacionados ao Uso de Substâncias/diagnóstico por imagemRESUMO
A common polymorphism (val158met) in the gene encoding catechol-O-methyltransferase (COMT) has been shown to affect dopamine (DA) tone in cortex and cortical functioning. D1 receptors are the main DA receptors in the cortex, and studies have shown that decreased levels of cortical DA are associated with upregulation of D1 receptor availability, as measured with the positron-emission tomography (PET) radiotracer [11C]NNC112. We compared [11C]NNC 112 binding in healthy volunteers homozygous for the Val allele compared with Met carriers. Subjects were otherwise matched for parameters known to affect [11C]NNC 112 binding. Subjects with Val/Val alleles had significantly higher cortical [11C]NNC 112 binding compared with Met carriers, but did not differ in striatal binding. These results confirm the prominent role of COMT in regulating DA transmission in cortex but not striatum, and the reliability of [11C]NNC 112 as a marker for low DA tone as previously suggested by studies in patients with schizophrenia.
Assuntos
Catecol O-Metiltransferase/genética , Córtex Cerebral/fisiologia , Corpo Estriado/fisiologia , Sistema Límbico/fisiologia , Polimorfismo de Nucleotídeo Único , Receptores de Dopamina D1/fisiologia , Adulto , Substituição de Aminoácidos , Benzazepinas , Benzofuranos , Mapeamento Encefálico/métodos , Feminino , Genótipo , Humanos , Masculino , Anamnese , Tomografia por Emissão de PósitronsRESUMO
RATIONALE: To examine the D2 occupancy of two commonly used antipsychotic medications and relate this to the D2 occupancy by endogenous dopamine in schizophrenia. OBJECTIVES: The aim of this study is to compare the occupancy of striatal D2 receptors by the atypical antipsychotic medications risperidone and olanzapine at fixed dosages and to estimate the effect on D2 occupancy by dopamine as a result of these treatments. METHODS: Seven patients with schizophrenia taking risperidone 6 mg/day and nine patients with schizophrenia taking olanzapine 10 mg/day underwent an [123I]IBZM SPECT scan after 3 weeks of treatment. The specific to non-specific equilibrium partition coefficient (V3") after bolus plus constant infusion of the tracer was calculated as [(striatal activity)/(cerebellar activity)]-1. D2 receptor occupancy was calculated by comparing V3" measured in treated patients to an age-corrected V3" value derived from a group of untreated patients with schizophrenia, previously published, according to the following formula: OCC=1-(V3" treated/V3" drug free). RESULTS: V3" was significantly lower in risperidone treated patients compared with olanzapine treated patients (0.23+/-0.06 versus 0.34+/-0.08, P=-0.01), which translated to a significantly larger occupancy in schizophrenic patients treated with risperidone compared to olanzapine (69+/-8% versus 55 +/-11%, P=0.01). Data from our previous study were used to calculate the occupancy of striatal D2 receptors by antipsychotic medications required to reduce the occupancy of these receptors by endogenous dopamine to control values. In medication-free patients with schizophrenia, the occupancy of striatal D2 receptors by endogenous dopamine is estimated at 15.8%. In healthy controls, the occupancy of striatal D2 receptors by dopamine is estimated at 8.8%. In order to reduce the dopamine occupancy of striatal D2 receptors in patients with schizophrenia to control values, 48% receptor occupancy by antipsychotic medications is required. CONCLUSIONS: These data indicate that the dosage of these medications, found to be effective in the treatment of schizophrenia, reduces DA stimulation of D2 receptors to levels slightly lower than those found in unmedicated healthy subjects.
Assuntos
Antipsicóticos/metabolismo , Benzodiazepinas/farmacologia , Receptores de Dopamina D2/metabolismo , Risperidona/farmacologia , Adulto , Algoritmos , Benzamidas , Dopamina/metabolismo , Feminino , Humanos , Masculino , Olanzapina , Escalas de Graduação Psiquiátrica , Pirrolidinas , Compostos Radiofarmacêuticos , Esquizofrenia/diagnóstico por imagem , Esquizofrenia/metabolismo , Tomografia Computadorizada de Emissão de Fóton ÚnicoRESUMO
Dopamine transmission in the ventral striatum (VST), a structure which includes the nucleus accumbens, ventral caudate, and ventral putamen, plays a critical role in the pathophysiology of psychotic states and in the reinforcing effects of virtually all drugs of abuse. The aim of this study was to assess the accuracy and precision of measurements of D(2) receptor availability in the VST obtained with positron emission tomography on the high-resolution ECAT EXACT HR+ scanner (Siemens Medical Systems, Knoxville, TN, U.S.A.). A method was developed for identification of the boundaries of the VST on coregistered high-resolution magnetic resonance imaging scans. Specific-to-nonspecific partition coefficient (V(3)") and binding potential (BP) of [(11)C]raclopride were measured twice in 10 subjects, using the bolus plus constant infusion method. [(11)C]Raclopride V(3)" in the VST (1.86 +/- 0.29) was significantly lower than in the dorsal caudate (DCA, 2.33 +/- 0.28) and dorsal putamen (DPU, 2.99 +/- 0.26), an observation consistent with postmortem studies. The reproducibility of V(3)" and BP were appropriate and similar in VST (V(3)" test-retest variability of 8.2% +/- 6.2%, intraclass correlation coefficient = 0.83), DCA (7.7% +/- 5.1%, 0.77), DPU (6.0% +/- 4.1%, 0.71), and striatum as a whole (6.3% +/- 4.1%, 0.78). Partial volume effects analysis revealed that activities in the VST were significantly contaminated by counts spilling over from the adjacent DCA and DPU: 70% +/- 5% of the specific binding measured in the VST originated from D(2) receptors located in the VST, whereas 12% +/- 3% and 18% +/- 3% were contributed by D(2) receptors in the DCA and DPU, respectively. Thus, accuracy of D(2) receptor measurement is improved by correction for partial voluming effects. The demonstration of an appropriate accuracy and precision of D(2) receptor measurement with [(11)C]raclopride in the VST is the first critical step toward the use of this ligand in the study of synaptic dopamine transmission at D(2) receptors in the VST using endogenous competition techniques.
Assuntos
Dopamina/metabolismo , Núcleo Accumbens/diagnóstico por imagem , Receptores de Dopamina D2/metabolismo , Tomografia Computadorizada de Emissão/métodos , Tomografia Computadorizada de Emissão/normas , Adulto , Artefatos , Radioisótopos de Carbono , Cerebelo/diagnóstico por imagem , Cerebelo/metabolismo , Antagonistas de Dopamina , Feminino , Haloperidol , Humanos , Masculino , Pessoa de Meia-Idade , Núcleo Accumbens/metabolismo , Racloprida , Reprodutibilidade dos TestesRESUMO
The science of quantitative analysis of PET and SPECT neuroreceptor imaging studies has grown considerably over the past decade. A number of methods have been proposed in which receptor parameter estimation results from fitting data to a model of the underlying kinetics of ligand uptake in the brain. These approaches have come to be collectively known as model-based methods and several have received widespread use. Here, we briefly review the most frequently used methods and examine their strengths and weaknesses. Kinetic modeling is the most direct implementation of the compartment models, but with some tracers accurate input function measurement and good compartment configuration identification can be difficult to obtain. Other methods were designed to overcome some particular vulnerability to error of classical kinetic modeling, but introduced new vulnerabilities in the process. Reference region methods obviate the need for arterial plasma measurement, but are not as robust to violations of the underlying modeling assumptions as methods using the arterial input function. Graphical methods give estimates of V(T) without the requirement of compartment model specification, but provide a biased estimator in the presence of statistical noise. True equilibrium methods are quite robust, but their use is limited to experiments with tracers that are suitable for constant infusion. In conclusion, there is no universally "best" method that is applicable to all neuroreceptor imaging studies, and carefully evaluation of model-based methods is required for each radiotracer.
Assuntos
Química Encefálica , Compostos Radiofarmacêuticos/metabolismo , Receptores de Superfície Celular/análise , Tomografia Computadorizada de Emissão de Fóton Único , Tomografia Computadorizada de Emissão , Animais , Humanos , Modelos BiológicosRESUMO
In fMRI, the issues involved in the control of type I error are fairly well understood. In contrast, the control of type II error has received less formal attention. This is perhaps due to the fact that the consideration of type II error requires the specification of an alternative hypothesis/experimental effect. In this paper, we present a method for expressing experimental effects in fMRI in a manner relative to a reference effect. A reference effect is chosen based on its neurophysiological significance to the researcher. This method provides a means to quantitatively express alternative hypotheses for fMRI, thus allowing type II error assessment prior to the collection of fMRI data. The simultaneous control of both type I and type II error should make meaningful interpretations possible from both positive and negative fMRI results.
Assuntos
Encéfalo/fisiologia , Imageamento por Ressonância Magnética/métodos , Modelos Neurológicos , Humanos , Técnicas In Vitro , Análise dos Mínimos Quadrados , Valores de ReferênciaRESUMO
Augmentation of selective serotonin reuptake inhibitors (SSRIs) therapy by the 5-HT(1A) receptor agent pindolol may reduce the delay between initiation of antidepressant treatment and clinical response. This hypothesis is based on the ability of pindolol to block 5-HT(1A) autoreceptors in the dorsal raphe nuclei (DRN) and to potentiate the increase in 5-HT transmission induced by SSRIs. However, placebo-controlled clinical studies of pindolol augmentation of antidepressant therapy have reported inconsistent results. Here, we evaluated the occupancy of 5-HT(1A) receptors during treatment with pindolol controlled release (CR) in nine healthy volunteers with Positron Emission Tomography and [11C]WAY 100635. Subjects were studied four times: at baseline, following one week of pindolol CR 7.5 mg/day (4 and 10 hrs post dose), and following one dose of pindolol CR 30 mg(4 hrs post dose). Occupancy of the DRN was 40 +/- 29% on scan 2, 38 +/- 26% on scan 3, and 64 +/- 15% on scan 4. The average occupancy in all other regions was significantly lower at each doses (18 +/- 5% on scan 2, 12 +/- 3% on scan 3, and 42 +/- 4% on scan 4). These results suggest that the blockade in the DRN reached in clinical studies (7.5 mg/day) might be too low and variable to consistently augment the therapeutic effect of SSRIs. However, these data indicate that pindolol exhibits in vivo selectivity for the DRN 5-HT(1A) autoreceptors. As DRN selectivity is desirable for potentiation of 5-HT function, this observation represents an important proof of concept for the development of 5-HT(1A) agents in this application.
Assuntos
Transtornos do Humor/tratamento farmacológico , Pindolol/farmacologia , Piperazinas/uso terapêutico , Piridinas/uso terapêutico , Núcleos da Rafe/metabolismo , Receptores de Serotonina/efeitos dos fármacos , Inibidores Seletivos de Recaptação de Serotonina/farmacologia , Adulto , Antidepressivos/uso terapêutico , Encéfalo/efeitos dos fármacos , Humanos , Cinética , Imageamento por Ressonância Magnética , Masculino , Pindolol/administração & dosagem , Pindolol/sangue , Pindolol/uso terapêutico , Piperazinas/sangue , Piperazinas/farmacocinética , Piridinas/sangue , Piridinas/farmacocinética , Receptores de Neurotransmissores/fisiologia , Receptores 5-HT1 de Serotonina , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Transmissão Sináptica/fisiologia , Tomografia Computadorizada de EmissãoRESUMO
UNLABELLED: Abnormal brain regional densities of serotonin (5-hydroxytryptamine [5-HT]) transporters have been reported in postmortem studies in several neuropsychiatric conditions, such as major depression and schizophrenia. trans-1,2,3,5,6,10-beta-Hexahydro-6-[4-(methylthio)phenyl]pyrrolo-[2,1-a]-isoquinoline ([11C]McN 5652) is the first PET radioligand successfully developed to label 5-HT transporters in the living human brain. The purpose of this study was to develop an imaging protocol and analytic method to measure regional 5-HT transporter binding potential (BP) with [11C]McN 5652 in humans. METHODS: The arterial input function and brain uptake of (+)-[11C]McN 5652 and (-)-[11C]McN 5652, the active and inactive enantiomers, respectively, were measured in 6 healthy volunteers. RESULTS: (+)-[11C]McN 5652 concentrated in brain regions rich in 5-HT transporters (midbrain, thalamus, basal ganglia, and medial temporal lobe structures), whereas the uptake of (-)-[11C]McN 5652 was more uniformly distributed. Total distribution volumes (V(T)) were derived using kinetic 2-compartment analysis and graphic analysis. V(T) derived by both methods were highly correlated. (+)-[11C]McN 5652 regional V(T) ranged from 18 +/- 2 mL/g in the cerebellum to 46 +/- 13 mL/g in the midbrain. (-)-[11C]McN 5652 regional VT ranged from 10 +/- 2 mL/g in the cerebellum to 14 +/- 3 mL/g in the thalamus. (+)-[11C]McN 5652 V(T) were higher than (-)-[11C]McN 5652 V(T) in all regions, including the cerebellum, a region devoid of 5-HT transporters. Blocking experiments were also performed in baboons with saturating doses of citalopram and in humans with nonsaturating doses of paroxetine. Cerebellar and neocortical (+)-[11C]McN 5652 V(T) were unaffected by pretreatment with 5-HT transporter blockers. In areas of high receptor concentration (midbrain, caudate, and thalamus) 5-HT transporter blockers decreased (+)-[11C]McN 5652 V(T) to the level of cerebellum (+)-[11C]McN 5652 V(T). CONCLUSION: These experiments indicate that the use of the difference between (+)- and (-)-[11C]McN 5652 V(T) to define specific binding to 5-HT transporters leads to an overestimation of specific binding. 5-HT transporter BP was derived as the difference between the regional and cerebellar (+)-[11C]McN 5652 V(T). BP values were in good agreement with the distribution of 5-HT transporters in the human brain, except for regions of relatively low 5-HT transporter concentration, such as the prefrontal cortex, where no specific binding was detected using (+)-[11C]McN 5652. (+)-[11C]McN 5652 is an appropriate radiotracer to quantify 5-HT transporters in regions with relatively high concentration of 5-HT transporters, such as the midbrain, thalamus, and basal ganglia, and should prove useful in elucidating abnormalities of 5-HT transmission in neuropsychiatric conditions.
Assuntos
Encéfalo/metabolismo , Proteínas de Transporte/metabolismo , Radioisótopos do Iodo/farmacocinética , Isoquinolinas/farmacocinética , Glicoproteínas de Membrana/metabolismo , Proteínas de Membrana Transportadoras , Proteínas do Tecido Nervoso , Antagonistas da Serotonina/farmacocinética , Adulto , Encéfalo/diagnóstico por imagem , Proteínas de Transporte/análise , Humanos , Cinética , Imageamento por Ressonância Magnética , Masculino , Glicoproteínas de Membrana/análise , Mesencéfalo/diagnóstico por imagem , Mesencéfalo/metabolismo , Valores de Referência , Proteínas da Membrana Plasmática de Transporte de Serotonina , Distribuição Tecidual , Tomografia Computadorizada de EmissãoRESUMO
In several positron-emission tomography studies of human subjects, analyses of data from the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor radioligand, [(11)C]WAY-100635 ¿[carbonyl-(11)C]N-(2-(4-methoxy-phenyl)-1-piperazin-1-yl)ethyl)-N -(2 -pyridyl)cyclohexanecarboxamide¿ have shown a discrepancy between the outcome measure k(3)/k(4) (binding potential normalized to cerebellum) as estimated by the simplified reference region method and results obtained by conventional kinetic modeling with an arterial input function. The reference region method has yielded results that are lower than the conventional approach, with the relative underestimation appearing to be an increasing function of k(3)/k(4). We performed simulations on idealized data to identify the source of the discrepancy. Both the simplified reference tissue model (SRTM) and the original full reference tissue model (FRTM) were tested to determine (a) if the error in estimated k(3)/k(4) is dependent on the blood flow in the region of interest relative to the blood flow in the region of reference (R(1)) and on the receptor density in the region of interest (true k(3)/k(4)), and (b) which violation of the reference model assumptions were responsible for this effect. FRTM returned parameter estimates that were independent and accurate if the reference region was constructed precisely as a one-tissue compartment model. SRTM overestimated k(3)/k(4) when the reference region was constructed as a one-tissue compartment model and underestimated k(3)/k(4) when the reference region was constructed as a two-tissue compartment model (which is the case for [(11)C]WAY-100635). In both cases, the magnitude of the error in k(3)/k(4) returned by SRTM was dependent on true R(1) and true k(3)/k(4). In conclusion, the SRTM is associated with a bias in the derivation of k(3)/k(4) that is not a simple scaling factor. This magnitude of these errors should be carefully evaluated for each new radioligand.
Assuntos
Radioisótopos de Carbono , Piperazinas/farmacocinética , Piridinas/farmacocinética , Receptores de Serotonina/análise , Antagonistas da Serotonina/farmacocinética , Humanos , Modelos Biológicos , Racloprida/farmacocinética , Receptores 5-HT1 de SerotoninaRESUMO
Preclinical studies in rodents suggest that augmentation of serotonin reuptake inhibitors (SSRIs) therapy by the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor agent pindolol might reduce the delay between initiation of treatment and antidepressant response. This hypothesis is based on the ability of pindolol to potentiate the increase in serotonin (5-HT) transmission induced by SSRIs, an effect achieved by blockade of the 5-HT(1A) autoreceptors in the dorsal raphe nuclei (DRN). However, placebo-controlled clinical studies of pindolol augmentation of antidepressant therapy have reported inconsistent results. Here, we evaluated the occupancy of 5-HT(1A) receptors following treatment with controlled release pindolol in nine healthy volunteers with positron-emission tomography (PET). Each subject was studied four times: at baseline (scan 1), following 1 week of oral administration of pindolol CR (7.5 mg/day) at peak level, 4 h after the dose (scan 2), and at 10 h following the dose (scan 3), and following one dose of pindolol CR (30 mg) (at peak level, 4 h) (scan 4). Pindolol occupancy of 5-HT(1A) receptors was evaluated in the DRN and cortical regions as the decrease in binding potential (BP) of the radiolabelled selective 5-HT(1A) antagonist [carbonyl-(11)C]WAY-100635 or [carbonyl-(11)C] N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridyl)cyclohexa necarboxamide abbreviated as [(11)C]WAY-100635. Pindolol dose-dependently decreased [(11)C]WAY-100635 BP. Combining all the regions, occupancy was 20 +/- 8% at scan 2, 14 +/- 8% at scan 3, and 44 +/- 8% at scan 4. The results of this study suggest that at doses used in clinical studies of augmentation of the SSRI effect by pindolol (2.5 mg t.i.d.), the occupancy of 5-HT(1A) receptors is moderate and highly variable between subjects. This factor might explain the variable results obtained in clinical studies. On the other hand, at each dose tested, pindolol occupancy of 5-HT(1A) receptors was higher in the DRN compared to cortical regions, demonstrating a significant in vivo selectivity for DRN 5-HT(1A) autoreceptors relative to cortico-limbic postsynaptic receptors. This selectivity is necessary for the potentiation of 5-HT transmission, and this finding represents an important proof of concept in the development of 5-HT(1A) agents for this application. Early evaluation of new drugs with PET imaging will enable rapid screening of compounds based on DRN selectivity and more appropriate determination of doses for clinical trials.
Assuntos
Pindolol/metabolismo , Receptores de Serotonina/análise , Antagonistas da Serotonina/metabolismo , Tomografia Computadorizada de Emissão , Adulto , Química Encefálica , Humanos , Masculino , Pessoa de Meia-Idade , Núcleos da Rafe/química , Receptores 5-HT1 de SerotoninaRESUMO
Serotonin 5-HT(1A) receptors are implicated in the pathophysiology of neuropsychiatric conditions. The goal of this study was to evaluate methods to derive 5-HT(1A) receptor parameters in the human brain with positron emission tomography (PET) and [carbonyl-(11)C]WAY 100635. Five healthy volunteer subjects were studied twice. Three methods of analysis were used to derive the binding potential (BP), and the specific to nonspecific equilibrium partition coefficient (k3/k4). Two methods, kinetic analysis based on a three compartment model and graphical analysis, used the arterial plasma time-activity curves as the input function to derive BP and k3/k4. A third method, the simplified reference tissue model (SRTM), derived the input function from uptake data of a region of reference, the cerebellum, and provided only k3/k4. All methods provided estimates of regional 5-HT(1A) receptor parameters that were highly correlated. Results were consistent with the known distribution of 5-HT(1A) receptors in the human brain. Compared with kinetic BP, graphical analysis slightly underestimated BP, and this phenomenon was mostly apparent in small size-high noise regions. Compared with kinetic k3/k4, the reference tissue method underestimated k3/k4 and the underestimation was apparent primarily in regions with high receptor density. Derivation of BP by both kinetic and graphical analysis was highly reliable, with an intraclass correlation coefficient (ICC) of 0.84 +/- 0.14 (mean +/- SD of 15 regions) and 0.84 +/- 0.19, respectively. In contrast, the reliability of k3/k4 was lower, with ICC of 0.53 +/- 0.28, 0.47 +/- 0.28, and 0.55 +/- 0.29 for kinetic, graphical, and reference tissue methods, respectively. In conclusion, derivation of BP by kinetic analysis using the arterial plasma input function appeared as the method of choice because of its higher test-retest reproducibility, lower vulnerability to experimental noise, and absence of bias.
Assuntos
Encéfalo/metabolismo , Receptores de Serotonina/metabolismo , Adulto , Encéfalo/diagnóstico por imagem , Cerebelo/metabolismo , Estudos de Avaliação como Assunto , Humanos , Cinética , Masculino , Modelos Biológicos , Piperazinas/farmacocinética , Piridinas/farmacocinética , Receptores de Serotonina/sangue , Receptores 5-HT1 de Serotonina , Reprodutibilidade dos Testes , Antagonistas da Serotonina/farmacocinética , Tomografia Computadorizada de EmissãoRESUMO
To evaluate the postulated role of extrastriatal D1 receptors in human cognition and psychopathology requires an accurate and reliable method for quantification of these receptors in the living human brain. [11C]NNC 112 is a promising novel radiotracer for positron emission tomography imaging of the D1 receptor. The goal of this study was to develop and evaluate methods to derive D1 receptor parameters in striatal and extrastriatal regions of the human brain with [11C]NNC 112. Six healthy volunteers were studied twice. Two methods of analysis (kinetic and graphical) were applied to 12 regions (neocortical, limbic, and subcortical regions) to derive four outcome measures: total distribution volume, distribution volume ratio, binding potential (BP), and specific-to-nonspecific equilibrium partition coefficient (k3/k4). Both kinetic and graphic analyses provided BP and k3/k4 values in good agreement with the known distribution of D1 receptors (striatum > limbic regions = neocortical regions > thalamus). The identifiability of outcome measures derived by kinetic analysis was excellent. Time-stability analysis indicated that 90 minutes of data collection generated stable outcome measures. Derivation of BP and k3/k4 by kinetic analysis was highly reliable, with intraclass correlation coefficients (ICCs) of 0.90+/-0.06 (mean +/- SD of 12 regions) and 0.84+/-0.11, respectively. The reliability of these parameters derived by graphical analysis was lower, with ICCs of 0.72+/-0.17 and 0.58+/-0.21, respectively. Noise analysis revealed a noise-dependent bias in the graphical but not the kinetic analysis. In conclusion, kinetic analysis of [11C]NNC 112 uptake provides an appropriate method with which to derive D1 receptor parameters in regions with both high (striatal) and low (extrastriatal) D1 receptor density.
Assuntos
Benzazepinas , Benzofuranos , Corpo Estriado/metabolismo , Receptores de Dopamina D1/metabolismo , Tomografia Computadorizada de Emissão/normas , Adulto , Artefatos , Benzazepinas/sangue , Benzazepinas/farmacocinética , Benzofuranos/sangue , Benzofuranos/farmacocinética , Radioisótopos de Carbono , Cerebelo/química , Cerebelo/diagnóstico por imagem , Cerebelo/metabolismo , Corpo Estriado/química , Corpo Estriado/diagnóstico por imagem , Antagonistas de Dopamina/farmacocinética , Feminino , Humanos , Cinética , Masculino , Pessoa de Meia-Idade , Neocórtex/química , Neocórtex/diagnóstico por imagem , Neocórtex/metabolismo , Ensaio Radioligante/métodos , Ensaio Radioligante/normas , Reprodutibilidade dos Testes , Tomografia Computadorizada de Emissão/métodosRESUMO
UNLABELLED: Because of its computational simplicity, the graphic method introduced by Logan et al. is frequently used to analyze time-activity curves of reversible radiotracers measured in brain regions with PET. The graphic method uses a nonlinear transformation of data to variables that have an asymptotically linear relationship. Compared with compartmental analysis of untransformed data, the graphic method enables derivation of regional distribution volumes that are free from assumptions about the underlying compartmental configuration. In this article, we describe statistical bias associated with this nonlinear transformation method. METHODS: Theoretic analysis, Monte Carlo simulation, and statistical analysis of PET data were used to test the graphic method for bias. RESULTS: Mean zero noise is associated with underestimation of distribution volumes when data are analyzed with graphic analysis, whereas this effect does not occur when the same data are analyzed by nonlinear regression and compartmental analysis. Moreover, this effect depends on the magnitude of the distribution volume, so that the bias is more pronounced in regions with high receptor density than regions with low receptor density or no receptors (region of reference). CONCLUSION: These results indicate that conventional kinetic analysis of untransformed data is less sensitive to mean zero noise than is graphic analysis of nonlinearly transformed data.